-
31.发明公开公开(公告)号：US20240216495A1
公开(公告)日：2024-07-04
申请号：US18446883
申请日：2023-08-09
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Nicholas Randolph Everard Kitchin , Justin Keith Moran , Louise Pedneault , Michael W. Pride , Mark Edward Ruppen , Christopher Frederick Webber
CPC classification number: A61K39/08 , A61K9/19 , A61K2039/545
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
32.发明公开公开(公告)号：US20240181028A1
公开(公告)日：2024-06-06
申请号：US18513738
申请日：2023-11-20
Applicant: Pfizer Inc.
Inventor： Catherine Alex , Annaliesa Sybil Anderson , Bishwa Raj Bhetuwal , Zecheng Chen , Kaushik Dutta , Caitlyn Gallagher , Jianxin Gu , Isis Kanevsky , Jin-Hwan Kim , Justin Keith Moran , Suddham Singh , Naveen Surendran , Abhishek Ravindra Vartak , YuYing Yang
CPC classification number: A61K39/092 , A61K47/646
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in Prevnar, Synflorix and/or Prevnar 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
-
33.发明申请公开(公告)号：US20220387576A1
公开(公告)日：2022-12-08
申请号：US17824295
申请日：2022-05-25
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Caitlyn Gallagher , Jianxin Gu , Isis Kanevsky , Jin-Hwan Kim , Justin Keith Moran , Suddham Singh , Naveen Surendran
Abstract: The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.
-
公开(公告)号：US11472850B2
公开(公告)日：2022-10-18
申请号：US17060067
申请日：2020-09-30
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC: C07K14/22 , A61K39/095 , A61K39/00
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
公开(公告)号：US20220136020A1
公开(公告)日：2022-05-05
申请号：US17431462
申请日：2020-02-20
Applicant: Pfizer Inc.
Inventor： Ling Chu , Scott Andrew Cook , Nishith Merchant , Justin Keith Moran
Abstract: The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides.
-
Patent Agency Ranking
公开(公告)号：US10829521B2
公开(公告)日：2020-11-10
申请号：US16713782
申请日：2019-12-13
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC: A61K39/095 , C07K14/22 , A61K39/00
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
公开(公告)号：US20200165582A1
公开(公告)日：2020-05-28
申请号：US16704744
申请日：2019-12-05
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20190112584A1
公开(公告)日：2019-04-18
申请号：US16104938
申请日：2018-08-19
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US09802987B2
公开(公告)日：2017-10-31
申请号：US14773324
申请日：2014-03-05
Applicant: PFIZER INC.
Inventor： Deborah Ann Dilts , Annaliesa Sybil Anderson , Kathrin Ute Jansen , Justin Keith Moran , Mark E Ruppen , Eugene Joseph Vidunas
IPC: A61K39/00 , A61K39/02 , A61K39/38 , A61K39/385 , C07K14/22 , A61K39/095 , C07K14/315 , A61K39/09
CPC classification number: C07K14/22 , A61K39/092 , A61K39/095 , A61K2039/6037 , A61K2039/6068 , C07K14/3156 , C07K2319/00 , C07K2319/55
Abstract: In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an ORF2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including ORF2086 polypeptide and a carrier polypeptide. The invention further includes immunogenic compositions and methods for inducing an immune response against Neisseria meningitidis in a mammal.
-
公开(公告)号：US09561269B2
公开(公告)日：2017-02-07
申请号：US14604620
申请日：2015-01-23
Applicant: PFIZER INC.
Inventor： Gary Warren Zlotnick , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen , Annaliesa Sybil Anderson , John Erwin Farley , Liesel A. Bernfield
IPC: A61K39/095 , C07K16/22 , C07K14/22 , C07K16/12 , A61K39/00
CPC classification number: A61K39/095 , A61K2039/55577 , A61K2039/6018 , C07K14/22 , C07K16/1217
Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
Abstract translation: 一方面，本发明涉及包含与SEQ ID NO：71具有至少95％同一性的氨基酸序列的分离多肽。另一方面，本发明涉及免疫原性组合物，其包含分离的非脂化非 - 来自脑膜炎奈瑟氏球菌血清群B的丙酮酸化ORF2086多肽和来自脑膜炎球菌血清群的至少一种共轭荚膜糖。
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.043 seconds)
